在古吉拉特邦南部三级医疗中心进行的回顾性-前瞻性队列联合研究，以了解接受抗结核治疗（ATT）的耐药结核病患者发生感音神经性听力损失的风险。
Combined Retrospective-Prospective Cohort Study to Know the Risk of Sensorineural Hearing Loss in Patients of Drug Resistant TB Receiving Anti Tuberculous Treatment (ATT) at Tertiary Care Centre in South Gujarat.
作者信息
Bhavsar Khushi N, Chaudhari Anandkumar V, Chauhan Jahanvika M, Patel Rahulkumar B, Contractor Jaymin A, Shamaliya Khyati D, Desai Pururava J, Roy Prachi P, Patel Hiteshri C
机构信息
Department of Otorhinolaryngology, Government Medical College, Surat, Gujarat India.
Department of Otorhinolaryngology, Baroda Medical College, Gujarat, India.
出版信息
Indian J Otolaryngol Head Neck Surg. 2023 Dec;75(4):3185-3190. doi: 10.1007/s12070-023-03702-8. Epub 2023 Jun 15.
Combined retrospective-prospective cohort study was done to know the risk of sensorineural hearing loss in patients of drug resistant Tuberculosis (TB) receiving Anti Tuberculous Treatment (ATT) at tertiary care centre in South Gujarat. Study was done by using retrospective and prospective data of the patients of drug resistant TB of NCHS who received injectable ATT and referred by department of Respiratory Medicine to ENT department for purpose of hearing evaluation pre and post treatment (Case cohort). Age and sex matched control cohort was also used which includes patients of non-drug resistant TB who were not receiving Injectable ATT. Incidence of SNHL in patients taking ATT for drug resistant tuberculosis in our study was 33.9%. The Relative Risk of SNHL was 14.3%. The Attributable Risk of SNHL (preventable SNHL) was 93%.
开展了一项回顾性-前瞻性队列研究，以了解在古吉拉特邦南部三级医疗中心接受抗结核治疗（ATT）的耐药结核病（TB）患者发生感音神经性听力损失的风险。该研究通过使用新儿童医院耐药结核病患者的回顾性和前瞻性数据进行，这些患者接受了注射用抗结核治疗，并由呼吸内科转诊至耳鼻喉科进行治疗前后的听力评估（病例队列）。还使用了年龄和性别匹配的对照队列，其中包括未接受注射用抗结核治疗的非耐药结核病患者。在我们的研究中，接受抗结核治疗的耐药结核病患者中感音神经性听力损失的发生率为33.9%。感音神经性听力损失的相对风险为14.3%。感音神经性听力损失的归因风险（可预防的感音神经性听力损失）为93%。
Zotero 插件